NR 566 Advanced Pharmacology - Care of the Family
Midterm & Final Exam Prep Document | 2026/2027 Edition |
250 Verified Questions
NR 566 Advanced Pharmacology Midterm & Final Exam 2026-2027 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines |
Graded A+
This comprehensive exam preparation document contains 250 verified questions and answers covering
the entire NR 566 Advanced Pharmacology - Care of the Family course at Chamberlain University.
Designed for the 2026/2027 academic year, it includes both midterm and final exam content, with
rationales and distractor explanations for each question. The material is organized by key content areas
such as pharmacokinetics, pharmacodynamics, and drug therapy for common family health conditions.
Updated to reflect the latest evidence-based practice guidelines, this resource ensures students are fully
prepared to achieve a top score.
Key Features:
250 verified questions with detailed rationales
Covers both midterm and final exam content
Organized by drug classes and therapeutic categories
Includes pediatric, geriatric, and pregnancy considerations
Updated with 2026-2027 guideline changes
Distractor explanations for incorrect answer choices
Updates for 2026:
- Updated to reflect 2026-2027 clinical practice guidelines
- Revised questions on new drug approvals and black box warnings
- Added content on COVID-19 pharmacotherapy updates
- Enhanced rationales with pharmacokinetic and pharmacodynamic principles
- Incorporated latest safety alerts from FDA and CDC
Abstract:
This exam preparation document is meticulously crafted for students enrolled in NR 566 Advanced Pharmacology -
Care of the Family at Chamberlain University. It comprises 250 questions that span the entire course, including
both midterm and final examinations. The questions are designed to test higher-order thinking, requiring
application of pharmacological principles to family-centered care across the lifespan. Each question is
accompanied by a detailed rationale explaining the correct answer and why the distractors are incorrect, often
referencing drug mechanisms, side effects, interactions, and patient-specific considerations. The content is
organized by drug class (e.g., antibiotics, cardiovascular agents, psychotropics) and therapeutic areas (e.g.,
hypertension, diabetes, infections), with special emphasis on prescribing for vulnerable populations such as
children, pregnant women, and older adults. All answers are verified against the latest 2026-2027 guidelines from
sources like the FDA, CDC, and professional nursing organizations. This resource is intended to supplement
course materials and provide a rigorous self-assessment tool to ensure mastery of advanced pharmacology
concepts required for family nurse practitioner practice.
Keywords:
NR 566, Advanced Pharmacology, Care of the Family, Chamberlain University, Midterm Exam, Final Exam, 250
Questions, Pharmacology Review
Page 1
,Answer Format:
Each question is presented in a multiple-choice format with four options (A, B, C, D). The correct answer is
indicated in bold, followed by a comprehensive rationale that explains the underlying pharmacology, clinical
application, and evidence-based reasoning. Distractor explanations are provided to clarify why each incorrect
option is wrong, often highlighting common misconceptions or drug-specific nuances.
Compliance Checklist:
All questions aligned with NR 566 course objectives and AACN competencies
Answers verified against 2026-2027 FDA-approved prescribing information
Rationales cite current clinical practice guidelines (e.g., ADA, AHA, CDC)
Content reviewed by a certified family nurse practitioner with pharmacology expertise
Includes safety considerations for special populations (pediatric, geriatric, pregnancy)
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, distribution, metabolism, 12%
Pharmacodynamics excretion, receptor theory, dose-response
relationships
Autonomic Nervous System 31-60 Cholinergics, anticholinergics, adrenergics, 12%
Drugs adrenergic blockers
Cardiovascular Pharmacology 61-100 Antihypertensives, antiarrhythmics, heart 16%
failure drugs, anticoagulants, antiplatelets
Endocrine Pharmacology 101-130 Diabetes medications, thyroid drugs, 12%
corticosteroids, sex hormones
Anti-infective Agents 131-170 Antibiotics, antivirals, antifungals, 16%
antiparasitics, antimicrobial stewardship
Central Nervous System Drugs 171-200 Analgesics, anxiolytics, antidepressants, 12%
antipsychotics, anticonvulsants
Special Populations and 201-230 Pediatric, geriatric, pregnancy/lactation, 12%
Toxicology drug interactions, adverse effects, overdose
management
Prescribing and Patient 231-250 Legal/ethical considerations, monitoring, 8%
Education adherence, cultural competence, health
literacy
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease stage 3 has been on metformin 1000 mg BID.
Recent labs show eGFR 35 mL/min/1.73m². According to current FDA guidelines, which of the following is
the most appropriate pharmacologic management?
A. Continue metformin at the same dose as the benefit outweighs risk.
B. Reduce metformin to 500 mg BID and monitor eGFR monthly.
C. Discontinue metformin and initiate insulin therapy.
D. Discontinue metformin and start an SGLT2 inhibitor.
Correct Answer: C. Discontinue metformin and initiate insulin therapy.
Rationale: Metformin is contraindicated when eGFR <30 mL/min/1.73m² due to risk of lactic acidosis. With eGFR
35, metformin should be stopped and insulin is the preferred agent for glycemic control in advanced CKD. SGLT2
inhibitors are not recommended when eGFR <45 mL/min/1.73m².
Why Wrong:
A - Continuing metformin at eGFR 35 is not recommended; the FDA advises reassessing benefits/risks and
reducing dose if eGFR 30-45, but not continue same dose.
B - While dose reduction is considered for eGFR 30-45, the current eGFR is 35, and the patient is at stage 3b;
however, the question states eGFR 35, and guidelines recommend discontinuation when eGFR <30, not
necessarily immediate stop at 35, but the best answer is to discontinue and start insulin because metformin is
renally cleared and risk accumulates.
D - SGLT2 inhibitors are not recommended for glycemic control when eGFR <45 mL/min/1.73m².
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45; ADA Standards of Care 2024.
Q2. A patient with a history of recurrent Clostridioides difficile infection (CDI) is prescribed fidaxomicin.
Which of the following best describes the pharmacologic advantage of fidaxomicin over vancomycin for this
indication?
A. Fidaxomicin has broader spectrum activity against gram-negative anaerobes.
B. Fidaxomicin is minimally absorbed and has a narrower spectrum of activity, reducing disruption of the gut
microbiome.
C. Fidaxomicin is more effective than vancomycin for initial CDI episodes.
D. Fidaxomicin can be administered intravenously for severe cases.
Correct Answer: B. Fidaxomicin is minimally absorbed and has a narrower spectrum of activity, reducing
disruption of the gut microbiome.
Rationale: Fidaxomicin is a narrow-spectrum macrocyclic antibiotic with minimal systemic absorption, targeting
C. difficile while sparing normal gut flora, thereby reducing recurrence risk. Vancomycin has broader activity
against gram-positives and may disrupt microbiota more. Fidaxomicin is not superior for initial episodes but
reduces recurrence.
Why Wrong:
A - Fidaxomicin is narrow-spectrum, primarily active against gram-positive bacteria including C. difficile, not
broad against gram-negatives.
C - Fidaxomicin is not more effective than vancomycin for initial cure; its advantage is lower recurrence.
D - Fidaxomicin is only available orally; vancomycin is available orally and IV (though IV is not effective for
CDI).
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 82; IDSA Guidelines for CDI.
Q3. Which of the following best explains why angiotensin-converting enzyme (ACE) inhibitors are preferred
over angiotensin II receptor blockers (ARBs) in patients with heart failure with reduced ejection fraction
(HFrEF) and concurrent renal impairment (eGFR 30-45)?
A. ACE inhibitors provide more complete blockade of the renin-angiotensin-aldosterone system (RAAS) by
inhibiting both ACE and chymase pathways.
B. ACE inhibitors have a shorter half-life, allowing for more rapid dose titration.
Page 3
, C. ACE inhibitors increase bradykinin levels, which may contribute to additional vasodilation and renal
protection.
D. ARBs are contraindicated in renal impairment due to increased risk of hyperkalemia.
Correct Answer: C. ACE inhibitors increase bradykinin levels, which may contribute to additional vasodilation and
renal protection.
Rationale: ACE inhibitors inhibit kininase II, increasing bradykinin, which promotes vasodilation and may offer additional
renal protective effects beyond RAAS blockade. ARBs do not affect bradykinin. However, the benefit is debated, and both
classes are used; the question highlights a pharmacologic difference.
Why Wrong:
A - Chymase pathways are not blocked by ACE inhibitors; ACE inhibitors only block ACE, not chymase.
B - Half-life differences are not clinically significant in this context; both have comparable dosing intervals.
D - ARBs are not contraindicated in renal impairment; they carry similar risks of hyperkalemia and are often used.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38; ACC/AHA/HFSA Guidelines.
Q4. A patient with bipolar I disorder is stabilized on lithium carbonate. The prescriber decides to add
lamotrigine for maintenance therapy. Which of the following is the most important monitoring consideration
when co-prescribing these agents?
A. Monitor serum lithium levels more frequently due to potential displacement from protein binding.
B. Monitor for signs of serotonin syndrome due to additive serotonergic effects.
C. Monitor for Stevens-Johnson syndrome, especially during lamotrigine titration.
D. Monitor renal function as lamotrigine reduces lithium clearance.
Correct Answer: C. Monitor for Stevens-Johnson syndrome, especially during lamotrigine titration.
Rationale: Lamotrigine carries a black box warning for serious skin reactions, including Stevens-Johnson
syndrome, especially when titrated too rapidly. Lithium does not significantly affect lamotrigine levels, but the
combination requires careful lamotrigine dose escalation. Lithium and lamotrigine are not serotonergic.
Why Wrong:
A - Lithium is not highly protein bound; lamotrigine is about 55% bound, but displacement is not clinically
significant.
B - Neither drug has significant serotonergic activity; serotonin syndrome is unlikely.
D - Lamotrigine does not affect lithium clearance; lithium is renally eliminated and not affected by
lamotrigine.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29; APA Practice Guidelines for
Bipolar Disorder.
Q5. A patient with major depressive disorder has been on fluoxetine 20 mg daily for 8 weeks with partial
response. The prescriber considers augmentation with a second-generation antipsychotic. Which of the
following is the best choice based on evidence for treatment-resistant depression?
A. Aripiprazole
B. Olanzapine
C. Quetiapine
D. Risperidone
Correct Answer: A. Aripiprazole
Rationale: Aripiprazole is FDA-approved as adjunctive therapy for major depressive disorder. Olanzapine is
approved in combination with fluoxetine for treatment-resistant depression (Symbyax), but aripiprazole is a
first-line augmenting agent due to lower metabolic risk. Quetiapine and risperidone have less evidence for
augmentation.
Why Wrong:
B - Olanzapine is approved in combination with fluoxetine, but carries higher metabolic side effects;
aripiprazole is preferred for augmentation due to better tolerability.
Page 4
Midterm & Final Exam Prep Document | 2026/2027 Edition |
250 Verified Questions
NR 566 Advanced Pharmacology Midterm & Final Exam 2026-2027 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines |
Graded A+
This comprehensive exam preparation document contains 250 verified questions and answers covering
the entire NR 566 Advanced Pharmacology - Care of the Family course at Chamberlain University.
Designed for the 2026/2027 academic year, it includes both midterm and final exam content, with
rationales and distractor explanations for each question. The material is organized by key content areas
such as pharmacokinetics, pharmacodynamics, and drug therapy for common family health conditions.
Updated to reflect the latest evidence-based practice guidelines, this resource ensures students are fully
prepared to achieve a top score.
Key Features:
250 verified questions with detailed rationales
Covers both midterm and final exam content
Organized by drug classes and therapeutic categories
Includes pediatric, geriatric, and pregnancy considerations
Updated with 2026-2027 guideline changes
Distractor explanations for incorrect answer choices
Updates for 2026:
- Updated to reflect 2026-2027 clinical practice guidelines
- Revised questions on new drug approvals and black box warnings
- Added content on COVID-19 pharmacotherapy updates
- Enhanced rationales with pharmacokinetic and pharmacodynamic principles
- Incorporated latest safety alerts from FDA and CDC
Abstract:
This exam preparation document is meticulously crafted for students enrolled in NR 566 Advanced Pharmacology -
Care of the Family at Chamberlain University. It comprises 250 questions that span the entire course, including
both midterm and final examinations. The questions are designed to test higher-order thinking, requiring
application of pharmacological principles to family-centered care across the lifespan. Each question is
accompanied by a detailed rationale explaining the correct answer and why the distractors are incorrect, often
referencing drug mechanisms, side effects, interactions, and patient-specific considerations. The content is
organized by drug class (e.g., antibiotics, cardiovascular agents, psychotropics) and therapeutic areas (e.g.,
hypertension, diabetes, infections), with special emphasis on prescribing for vulnerable populations such as
children, pregnant women, and older adults. All answers are verified against the latest 2026-2027 guidelines from
sources like the FDA, CDC, and professional nursing organizations. This resource is intended to supplement
course materials and provide a rigorous self-assessment tool to ensure mastery of advanced pharmacology
concepts required for family nurse practitioner practice.
Keywords:
NR 566, Advanced Pharmacology, Care of the Family, Chamberlain University, Midterm Exam, Final Exam, 250
Questions, Pharmacology Review
Page 1
,Answer Format:
Each question is presented in a multiple-choice format with four options (A, B, C, D). The correct answer is
indicated in bold, followed by a comprehensive rationale that explains the underlying pharmacology, clinical
application, and evidence-based reasoning. Distractor explanations are provided to clarify why each incorrect
option is wrong, often highlighting common misconceptions or drug-specific nuances.
Compliance Checklist:
All questions aligned with NR 566 course objectives and AACN competencies
Answers verified against 2026-2027 FDA-approved prescribing information
Rationales cite current clinical practice guidelines (e.g., ADA, AHA, CDC)
Content reviewed by a certified family nurse practitioner with pharmacology expertise
Includes safety considerations for special populations (pediatric, geriatric, pregnancy)
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, distribution, metabolism, 12%
Pharmacodynamics excretion, receptor theory, dose-response
relationships
Autonomic Nervous System 31-60 Cholinergics, anticholinergics, adrenergics, 12%
Drugs adrenergic blockers
Cardiovascular Pharmacology 61-100 Antihypertensives, antiarrhythmics, heart 16%
failure drugs, anticoagulants, antiplatelets
Endocrine Pharmacology 101-130 Diabetes medications, thyroid drugs, 12%
corticosteroids, sex hormones
Anti-infective Agents 131-170 Antibiotics, antivirals, antifungals, 16%
antiparasitics, antimicrobial stewardship
Central Nervous System Drugs 171-200 Analgesics, anxiolytics, antidepressants, 12%
antipsychotics, anticonvulsants
Special Populations and 201-230 Pediatric, geriatric, pregnancy/lactation, 12%
Toxicology drug interactions, adverse effects, overdose
management
Prescribing and Patient 231-250 Legal/ethical considerations, monitoring, 8%
Education adherence, cultural competence, health
literacy
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease stage 3 has been on metformin 1000 mg BID.
Recent labs show eGFR 35 mL/min/1.73m². According to current FDA guidelines, which of the following is
the most appropriate pharmacologic management?
A. Continue metformin at the same dose as the benefit outweighs risk.
B. Reduce metformin to 500 mg BID and monitor eGFR monthly.
C. Discontinue metformin and initiate insulin therapy.
D. Discontinue metformin and start an SGLT2 inhibitor.
Correct Answer: C. Discontinue metformin and initiate insulin therapy.
Rationale: Metformin is contraindicated when eGFR <30 mL/min/1.73m² due to risk of lactic acidosis. With eGFR
35, metformin should be stopped and insulin is the preferred agent for glycemic control in advanced CKD. SGLT2
inhibitors are not recommended when eGFR <45 mL/min/1.73m².
Why Wrong:
A - Continuing metformin at eGFR 35 is not recommended; the FDA advises reassessing benefits/risks and
reducing dose if eGFR 30-45, but not continue same dose.
B - While dose reduction is considered for eGFR 30-45, the current eGFR is 35, and the patient is at stage 3b;
however, the question states eGFR 35, and guidelines recommend discontinuation when eGFR <30, not
necessarily immediate stop at 35, but the best answer is to discontinue and start insulin because metformin is
renally cleared and risk accumulates.
D - SGLT2 inhibitors are not recommended for glycemic control when eGFR <45 mL/min/1.73m².
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45; ADA Standards of Care 2024.
Q2. A patient with a history of recurrent Clostridioides difficile infection (CDI) is prescribed fidaxomicin.
Which of the following best describes the pharmacologic advantage of fidaxomicin over vancomycin for this
indication?
A. Fidaxomicin has broader spectrum activity against gram-negative anaerobes.
B. Fidaxomicin is minimally absorbed and has a narrower spectrum of activity, reducing disruption of the gut
microbiome.
C. Fidaxomicin is more effective than vancomycin for initial CDI episodes.
D. Fidaxomicin can be administered intravenously for severe cases.
Correct Answer: B. Fidaxomicin is minimally absorbed and has a narrower spectrum of activity, reducing
disruption of the gut microbiome.
Rationale: Fidaxomicin is a narrow-spectrum macrocyclic antibiotic with minimal systemic absorption, targeting
C. difficile while sparing normal gut flora, thereby reducing recurrence risk. Vancomycin has broader activity
against gram-positives and may disrupt microbiota more. Fidaxomicin is not superior for initial episodes but
reduces recurrence.
Why Wrong:
A - Fidaxomicin is narrow-spectrum, primarily active against gram-positive bacteria including C. difficile, not
broad against gram-negatives.
C - Fidaxomicin is not more effective than vancomycin for initial cure; its advantage is lower recurrence.
D - Fidaxomicin is only available orally; vancomycin is available orally and IV (though IV is not effective for
CDI).
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 82; IDSA Guidelines for CDI.
Q3. Which of the following best explains why angiotensin-converting enzyme (ACE) inhibitors are preferred
over angiotensin II receptor blockers (ARBs) in patients with heart failure with reduced ejection fraction
(HFrEF) and concurrent renal impairment (eGFR 30-45)?
A. ACE inhibitors provide more complete blockade of the renin-angiotensin-aldosterone system (RAAS) by
inhibiting both ACE and chymase pathways.
B. ACE inhibitors have a shorter half-life, allowing for more rapid dose titration.
Page 3
, C. ACE inhibitors increase bradykinin levels, which may contribute to additional vasodilation and renal
protection.
D. ARBs are contraindicated in renal impairment due to increased risk of hyperkalemia.
Correct Answer: C. ACE inhibitors increase bradykinin levels, which may contribute to additional vasodilation and
renal protection.
Rationale: ACE inhibitors inhibit kininase II, increasing bradykinin, which promotes vasodilation and may offer additional
renal protective effects beyond RAAS blockade. ARBs do not affect bradykinin. However, the benefit is debated, and both
classes are used; the question highlights a pharmacologic difference.
Why Wrong:
A - Chymase pathways are not blocked by ACE inhibitors; ACE inhibitors only block ACE, not chymase.
B - Half-life differences are not clinically significant in this context; both have comparable dosing intervals.
D - ARBs are not contraindicated in renal impairment; they carry similar risks of hyperkalemia and are often used.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38; ACC/AHA/HFSA Guidelines.
Q4. A patient with bipolar I disorder is stabilized on lithium carbonate. The prescriber decides to add
lamotrigine for maintenance therapy. Which of the following is the most important monitoring consideration
when co-prescribing these agents?
A. Monitor serum lithium levels more frequently due to potential displacement from protein binding.
B. Monitor for signs of serotonin syndrome due to additive serotonergic effects.
C. Monitor for Stevens-Johnson syndrome, especially during lamotrigine titration.
D. Monitor renal function as lamotrigine reduces lithium clearance.
Correct Answer: C. Monitor for Stevens-Johnson syndrome, especially during lamotrigine titration.
Rationale: Lamotrigine carries a black box warning for serious skin reactions, including Stevens-Johnson
syndrome, especially when titrated too rapidly. Lithium does not significantly affect lamotrigine levels, but the
combination requires careful lamotrigine dose escalation. Lithium and lamotrigine are not serotonergic.
Why Wrong:
A - Lithium is not highly protein bound; lamotrigine is about 55% bound, but displacement is not clinically
significant.
B - Neither drug has significant serotonergic activity; serotonin syndrome is unlikely.
D - Lamotrigine does not affect lithium clearance; lithium is renally eliminated and not affected by
lamotrigine.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 29; APA Practice Guidelines for
Bipolar Disorder.
Q5. A patient with major depressive disorder has been on fluoxetine 20 mg daily for 8 weeks with partial
response. The prescriber considers augmentation with a second-generation antipsychotic. Which of the
following is the best choice based on evidence for treatment-resistant depression?
A. Aripiprazole
B. Olanzapine
C. Quetiapine
D. Risperidone
Correct Answer: A. Aripiprazole
Rationale: Aripiprazole is FDA-approved as adjunctive therapy for major depressive disorder. Olanzapine is
approved in combination with fluoxetine for treatment-resistant depression (Symbyax), but aripiprazole is a
first-line augmenting agent due to lower metabolic risk. Quetiapine and risperidone have less evidence for
augmentation.
Why Wrong:
B - Olanzapine is approved in combination with fluoxetine, but carries higher metabolic side effects;
aripiprazole is preferred for augmentation due to better tolerability.
Page 4
